NVO NVO

The Most Overlooked Reason Eli Lilly Stock Keeps Surging -- and It Has Nothing to Do With Weight Loss

The Motley Fool · 9h ago

Wegovy Pill Just Changed the GLP-1 Market. Here's Why Eli Lilly Stock Could Still Win

The Motley Fool · 16h ago

Clinical Stage Partnering Terms and Agreements in Pharmaceuticals and Biotechnology 2020-2026 | Benchmark More Than 1,800 Biopharma Deals with Various Indexes

GlobeNewswire Inc. · 23h ago

Oral Obesity Therapies Market to Reach $6.32 Billion by 2030 as Demand for GLP-1 Treatments Accelerates

GlobeNewswire Inc. · 3d ago

Is This Disturbing Trend Bad News for Eli Lilly in the Billion-Dollar Obesity Drug Market?

The Motley Fool · 4d ago

Global Blood Glucose Monitoring System Market Size to Reach USD 39.4 Billion by 2035 | Growing at 8.9% CAGR | Industry Trends, Market Share & Forecast – Custom Market Insights

GlobeNewswire Inc. · 4d ago

3 Dividend Stocks That Are No-Brainer Buys Heading Into the Second Half of 2026

The Motley Fool · 6d ago

Heartflow vs. Omeros: Which Healthcare Innovator Stock Is a Better Buy in 2026?

The Motley Fool · 9d ago

Is It Too Late to Buy Eli Lilly?

The Motley Fool · 9d ago

Prediction: Eli Lilly Stock Will Hit This Price by the End of 2026

The Motley Fool · 9d ago

Eli Lilly and Novo Nordisk Are Fine -- but These 2 Stocks Could Be an Even Better Way to Invest in the GLP-1 Boom

The Motley Fool · 10d ago

Hims & Hers Pullback Could Create a Better Entry Into GLP-1 Demand

Investing.com · 10d ago

Is It Too Late to Buy Eli Lilly Stock? Here's What $1,000 Invested Today Could Be Worth in 10 Years.

The Motley Fool · 10d ago

Eli Lilly and vs. Teva: Which Pharmaceutical Stock Is a Better Buy in 2026?

The Motley Fool · 11d ago

Could This Healthcare Stock Help You Build a Real Fortune Over the Next 20 Years?

The Motley Fool · 11d ago

How Much Could $1,000 Invested in Viking Therapeutics Be Worth by 2030?

The Motley Fool · 13d ago

Is Viking Therapeutics Stock Going to $50? Here's What the Bulls and Bears Are Saying

The Motley Fool · 14d ago

Johnson & Johnson Is Walking Away From a $100 Billion Obesity Market. Could That Actually Make It the Better Long-Term Buy Than Eli Lilly?

The Motley Fool · 14d ago

Here's Why Viking Therapeutics Stock Surged Higher in June

The Motley Fool · 14d ago

Big Pharma Has a Case of Merger Mania

The Motley Fool · 18d ago

Is Septerna a Stock to Sell After an Insider Let Go of 15,000 Shares?

The Motley Fool · 18d ago

2 Top Growth Stocks to Buy Right Now Without Hesitation

The Motley Fool · 19d ago

Opinion: Pfizer Is a Fantastic Dividend Stock for Income Investors to Buy Right Now

The Motley Fool · 20d ago

Is Eli Lilly Stock an Undervalued Healthcare Stock to Buy?

The Motley Fool · 21d ago

An Analyst Just Declared Eli Lilly the "Clear Winner" of an American Diabetes Association Conference Focused on Weight-Loss Drugs. Novo's Chief Scientist Disagrees. Who's Right?

The Motley Fool · 22d ago